CLOs on the Move

Milestone Pharmaceuticals

www.milestonepharma.com

 
Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in ...
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.milestonepharma.com
  • 1111 Dr Frederik Philips Blvd Suite 420
    Saint Laurent, QC CAN H4M 2X6
  • Phone: 514.336.0444

Executives

Name Title Contact Details

Similar Companies

Bi-Coastal Pharmaceutical Corp

Bi-Coastal Pharmaceutical Corp is a Red Bank, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

PanTheryx

PanTheryx, Inc., a U.S. medical nutrition company based in Boulder, Colorado, is dedicated to improving global health and quality of life through innovative science.

Creyon Bio

Creyon Bio is a company that is reinventing drug development from the ground up to make safe, effective oligonucleotide based medicines possible—on demand.

Pliant Therapeutics

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant`s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.